Endovia Health Sciences (EDVA) Q2 2026 earnings summary

Executive summary

• Transitioned from beverage business to cannabinoid health and wellness platform in Q2 2026, including a corporate name change to Endovia Health Sciences, Inc. effective August 2026.

• Strategic transformation underway, shifting focus from alcoholic beverages to cannabinoid health and wellness products.

• Acquired exclusive global rights to CannEpil®, a cannabinoid pharmaceutical for epilepsy, and expanded its license to veterinary uses.

• Discontinued legacy beverage operations, including Copa Di Vino, due to lack of working capital and strategic shift.

Financial highlights

• Net loss from continuing operations was $2.0 million for Q2 2026, compared to $8.4 million in Q2 2025; net loss for the six months ended June 30, 2026 was $4.1 million, down from $11.6 million year-over-year.

• Loss from continuing operations declined by approximately 64% for the first six months of 2026 compared to the same period in 2025, driven by significant cost-reduction initiatives.

• Revenues for the six months ended June 30, 2026 were less than $0.01 million, down from $0.05 million in the prior year period; no revenue in Q2 2026.

• Operating expenses for Q2 2026 were $2.0 million, up from $1.5 million in Q2 2025, driven by increased non-cash share-based compensation and new business activities.

• Cash and cash equivalents were $242,702 as of June 30, 2026, compared to $281,435 at December 31, 2025.

Outlook and guidance

• Focused on developing and commercializing CannEpil® for human and veterinary use, with milestone-based collaboration agreements in place.

• Management expects continued progress in reducing losses and building a diversified cannabinoid-based health sciences platform.

• Management is pursuing additional funding and strategic partnerships to support ongoing operations and regulatory milestones.

• NYSE American accepted the company’s compliance plan, providing a compliance period through January 29, 2027.